Clovis Oncology, Inc. focuses on developing targeted therapies for cancer treatment, particularly in the area of ovarian cancer with its lead product, Rubraca. The company operates primarily in the United States and Europe, leveraging its expertise in biomarker-driven therapies to differentiate itself in a competitive oncology market.
Business Overview
Clovis generates revenue primarily through the sale of its FDA-approved drug Rubraca, which targets specific genetic mutations in cancer patients. The company's competitive advantage lies in its focus on precision medicine and the ability to identify patients who are most likely to benefit from its therapies, allowing for higher pricing power and improved patient outcomes.
FDA approval of new indications for Rubraca
Clinical trial results impacting drug efficacy and safety
Partnerships or collaborations with larger pharmaceutical companies
Changes in reimbursement policies affecting drug accessibility
Risk Factors
Regulatory changes impacting drug approval processes
Technological disruption in cancer treatment methodologies
Emergence of new therapies from competitors that could capture market share
Pricing pressures from generic alternatives as patents expire
High cash burn rate leading to potential liquidity issues
Dependence on successful fundraising to sustain operations
Macro Sensitivity
low - The demand for oncology drugs is relatively inelastic, as cancer treatments are often prioritized regardless of economic conditions.
Clovis is sensitive to interest rates as higher rates could increase the cost of capital for funding clinical trials and operations, potentially delaying growth initiatives.
minimal - The company has a negative debt/equity ratio, indicating a lack of reliance on debt financing.
Profile
growth - Investors seeking high-risk, high-reward opportunities in the biotech sector may find Clovis attractive due to its focus on innovative cancer therapies.
high - The stock has shown significant volatility, particularly with its recent performance decline.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
